Could ASTELLAS PHARMA INC ORDINARY SHARES JAP (OTCMKTS:ALPMF) See a Reversal After More Sellers Came In?

April 17, 2018 - By Dolores Ford

Astellas Pharma Inc. (OTCMKTS:ALPMF) Logo

The stock of ASTELLAS PHARMA INC ORDINARY SHARES JAP (OTCMKTS:ALPMF) registered an increase of 41.08% in short interest. ALPMF’s total short interest was 5.50 million shares in April as published by FINRA. Its up 41.08% from 3.90 million shares, reported previously. With 2,200 shares average volume, it will take short sellers 2502 days to cover their ALPMF’s short positions. The short interest to ASTELLAS PHARMA INC ORDINARY SHARES JAP’s float is 0.28%.

It closed at $14.8 lastly. It is up 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Astellas Pharma Inc., a pharmaceutical company, makes, markets, and imports and exports pharmaceutical products worldwide. The company has market cap of $29.40 billion. The firm offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It has a 17.81 P/E ratio. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: